Cornea and external disease

FDA approves treatment for neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration has approved satralizumab-mwge (Enspryng; Genentech) for adults with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disorder of the central nervous system that damages the optic nerve and spinal cord, according to a press release.

It is the only approved treatment for NMOSD that inhibits interleukin-6 receptor activity, using novel recycling antibody technology. …

Read More


featured stories

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. May 25, 2020

Transcutaneous Electrical Nerve Stimulation Demonstrates Long-term Reduction of Ocular Pain

Use of a transcutaneous electrical nerve stimulation (TENS) can significantly reduce subjective pain intensity, according to a poster presented at the American Society of Cataract and Refractive Surgery (ASCRS) virtual annual…

View All

Journal Scan

  1. Aug 14, 2020

Switching to infliximab biosimilar may lead to more ocular flares in for non-infectious uveitis

Switching from infliximab to a biosimilar infliximab-abda for non-infectious uveitis may lead to more ocular flares, according to a study published in the American Journal of Ophthalmology.

In this retrospective case series, 17 patients…

View All

Trending Topics

  1. Aug 16, 2020

FDA approves treatment for neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration has approved satralizumab-mwge (Enspryng; Genentech) for adults with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disorder of the central nervous system that…

View All

Resources